Caribou Biosciences Inc CRBU.OQ CRBU.O is expected to show a rise in quarterly revenue when it reports results on March 2 (estimated) for the period ending December 31 2025
The Berkeley California-based company is expected to report a 21.5% increase in revenue to $2.523 million from $2.08 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Caribou Biosciences Inc is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Caribou Biosciences Inc is $9.00, about 352.3% above its last closing price of $1.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.35 | -0.36 | -0.30 | Beat | 16.7 |
Jun. 30 2025 | -0.41 | -0.39 | -0.58 | Missed | -48 |
Mar. 31 2025 | -0.45 | -0.44 | -0.43 | Beat | 2.8 |
Dec. 31 2024 | -0.42 | -0.42 | -0.39 | Beat | 7.2 |
Sep. 30 2024 | -0.47 | -0.45 | -0.38 | Beat | 15.5 |
Jun. 30 2024 | -0.46 | -0.46 | -0.42 | Beat | 8.3 |
Mar. 31 2024 | -0.40 | -0.40 | -0.46 | Missed | -16.2 |
Dec. 31 2023 | -0.34 | -0.37 | -0.39 | Missed | -6.1 |
This summary was machine generated February 27 at 22:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)